The thing with EXAS is fears of competition, namely blood drawn tests that are being developed, have done nothing to stop the share price from marching upwards. Time and time again, I have been proven that “fears” of “potential” competition is not a reason to sell a stock. When competition actually starts taking a bite, that’s when you have to reassess. That and them blaming a slowdown during the last flu season because of doctors being too busy with the flu, seemed a little odd to me. So congrats for hanging on. The more observations and case studies you have, the better your framework for evaluating companies going forward. I know EXAS is working on a lot of things too so I don’t expect them to be a “one hit wonder” for long.
2 Likes